EDITAS MEDICINE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
EDITAS MEDICINE, INC. (EDIT) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 445.13 thousand shares for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2019-11-12
- EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-09-30 was 44.40K shares.
- EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-06-30 was 10.07K shares.
- EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-03-31 was 390.65K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month |
|---|---|---|---|
| 2019-09-30 | 44.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 54.48K shares derived: sum of 2 quarters · filed 2019-11-12 | 445.13K shares 10-Q · filed 2019-11-12 |
| 2019-06-30 | 10.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 400.72K shares 10-Q · filed 2019-08-07 | |
| 2019-03-31 | 390.65K shares 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |